TABLE 2.
Treatment Characteristics: Few Doses Tolerated Before Debilitating Disease Progression
Total Doses | No. Patients |
---|---|
1 | 3 |
2 | 8* |
3 | 4 |
4 (1 course) | 7† |
5 | |
6 | 2 |
7 | 1 |
8 (2 courses) | 2 |
Grade 3 to 4 Immune-mediated adverse events | |
Colitis | 1 |
Hypophysitis | 1 |
Encephalitis | 1 |
1 stopped for colitis, 1 stopped for encephalitis.
1 stopped for hypophysitis.